The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

Rhea-AI Summary

The Oncology Institute (NASDAQ: TOI) appointed Kim Tzoumakas to its Board of Directors, effective February 23, 2026.

Ms. Tzoumakas brings more than two decades of executive leadership in oncology, pharmacy services and healthcare operations, currently serving as CEO of VytlOne National Pharmacy Services and with prior CEO and board experience.

Positive

• Board appointment effective Feb 23, 2026
• Adds 20+ years oncology and pharmacy leadership
• Current CEO of VytlOne National Pharmacy Services
• Prior CEO who led operational turnaround and strategic sale
• Board experience at multiple public and private healthcare companies

Negative

• None.

CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has served on the board of several private and public healthcare companies including SeaSpine, Coherus BioSciences, Ob Hospitalist Group and most recently, VytlOne.

“We are thrilled to welcome Kim to our Board of Directors,” said Daniel Virnich, MD, CEO of The Oncology Institute. “Her deep experience in both oncology and pharmacy services are particularly relevant at this point in TOI’s journey as we expand our care delivery model across employed and MSO networks and grow our pharmacy business. Kim’s proven track record of expanding access, improving cost management, and advancing integrated care delivery models, will be invaluable as to our company and further strengthen our already outstanding board of directors.”

“It’s an honor to have been selected as a Board member of The Oncology Institute,” said Ms. Tzoumakas. “I look forward to utilizing my background and experience in healthcare services to advise this dedicated team and help them accomplish their mission of improving cancer outcomes and streamlining the patient journey.”

About The Oncology Institute (www.theoncologyinstitute.com):
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.

Media
The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors
ICR Healthcare
TOI@icrhealthcare.com

FAQ

Who is Kim Tzoumakas and why did The Oncology Institute (TOI) appoint her to the board?

She is an executive with 20+ years in oncology and pharmacy services, appointed to TOI's board effective February 23, 2026. According to the company, her operational turnaround and pharmacy experience are expected to support TOI's care delivery expansion and pharmacy business growth.

When does Kim Tzoumakas officially join The Oncology Institute board (TOI)?

Kim Tzoumakas joined TOI's Board of Directors effective February 23, 2026. According to the company, the appointment is immediate and intended to support near-term expansion of employed and MSO care delivery networks and pharmacy initiatives.

What relevant experience does Kim Tzoumakas bring to TOI's board that could affect TOI (NASDAQ: TOI)?

She brings leadership across oncology, pharmacy services and healthcare operations, including CEO roles and board seats. According to the company, this experience is relevant to expanding access, cost management, and integrated care delivery at TOI.

How might Kim Tzoumakas' role as VytlOne CEO influence TOI's pharmacy business (TOI)?

Her current CEO role at VytlOne brings direct pharmacy services expertise that could inform TOI's pharmacy growth strategy. According to the company, her background supports operational scaling and potential integration across TOI's pharmacy initiatives.

Does Kim Tzoumakas have prior board and turnaround experience relevant to TOI's strategy (TOI)?

Yes; she previously served on several public and private healthcare boards and led a multi-year turnaround culminating in a strategic sale. According to the company, these experiences align with TOI's focus on expanding care models and improving cost management.